p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors
Triple-negative breast cancers (TNBCs) lack effective targeted therapies, and cytotoxic chemotherapies remain the standard of care for this subtype. Owing to their increased genomic instability, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are being tested against TNBCs. In particular, cli...
Збережено в:
| Автори: | , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
American Society for Clinical investigation
2021-02-01
|
| Серія: | JCI Insight |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1172/jci.insight.138382 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|